Expression and clinical significance of cell cycle protein-dependent kinase 1 and aurora kinase A in the serum of patients with hepatitis B virus-related hepatocellular carcinoma
- VernacularTitle:细胞周期蛋白依赖性激酶1(CDK1)和极光激酶A(AURKA)在HBV相关肝细胞癌患者血清中的表达及意义
- Author:
Yanfang HE
1
;
Jiaojiao XIE
1
;
Lanlan ZHENG
1
;
Cai GUO
1
;
Yanhua MA
1
Author Information
- Publication Type:Journal Article
- Keywords: Carcinoma, Hepatocellular; Cyclin-Dependent Kinases; Aurora Kinase A
- From: Journal of Clinical Hepatology 2024;40(7):1390-1396
- CountryChina
- Language:Chinese
- Abstract: ObjectiveTo investigate the value of serum cell cycle protein-dependent kinase 1 (CDK1) and aurora kinase A (AURKA) in the diagnosis of patients with hepatitis B virus-related hepatocellular carcinoma (HBV-HCC). MethodsA total of 50 HBV-HCC patients, 50 patients with hepatitis B virus-related liver cirrhosis (HBV-LC), and 50 chronic hepatitis B (CHB) patients who were hospitalized in Department of Gastroenterology, Gansu Provincial Hospital, from June 2022 to December 2023 were enrolled, and 50 healthy individuals, matched for age and sex, who received physical examination at Physical Examination Center during the same period of time were enrolled as control group. Related data were recorded for all patients, including age, sex, complications, and the results of routine blood test, liver function, and coagulation for the first time after admission. ELISA was used to measure the serum levels of CDK1 and AURKA. A one-way analysis of variance was used for comparison of normally distributed continuous data between multiple groups, and the least significant difference t-test was used for further comparison between two groups; the Kruskal-Wallis H test was used for comparison of non-normally distributed continuous data between multiple groups and the least significant difference Bonferroni test was used for further comparison between two groups; the chi-square test or the Fisher’s exact test was used for comparison of categorical data between groups. The Spearman correlation analysis was used to investigate the correlation between CDK1 and AURKA, and the receiver operating characteristic (ROC) curve and the area under the ROC curve (AUC) were used to investigate the value of CDK1 and AURKA in the diagnosis of HBV-HCC. ResultsThere were significant differences in liver function parameters between the HBV-HCC patients and the control group (all P<0.05); there were significant differences between the CHB group and the HBV-HCC group in albumin, Glb, direct bilirubin, aspartate aminotransferase (AST), gamma-glutamyl transpeptidase (GGT), and alkaline phosphatase (all P<0.05); there were significant differences between the HBV-LC group and the HBV-HCC group in Glb, AST, and GGT (all P<0.05). The HBV-HCC group had significantly higher serum levels of CDK1 and AURKA than the HBV-LC group, the CHB group, and the control group (all P<0.05). There was a significant positive correlation between CDK1 and AURKA in the overall study population and the HBV-HCC patients (r=0.526 6 and 0.815 2, P<0.001). With the control group as reference, CDK1 had an AUC of 0.832 3 in the diagnosis of HBV-HCC, with a sensitivity of 92.86% and a specificity of 75%, and AURKA had an AUC of 0.886 6 in the diagnosis of HCC, with a sensitivity of 95.80% and a specificity of 74%. With the CHB group as reference, CDK1 had an AUC of 0.833 3 in the diagnosis of HBV-HCC, with a sensitivity of 93.75% and a specificity of 75%, and AURKA had an AUC of 0.972 7 in the diagnosis of HBV-HCC, with a sensitivity of 95.83% and a specificity of 91.67%. With the HBV-LC group as reference, CDK1 had an AUC of 0.608 5 in the diagnosis of HBV-HCC, with a sensitivity of 66.67% and a specificity of 54.17%, and AURKA had an AUC of 0.762 2 in the diagnosis of HBV-HCC, with a sensitivity of 95.83% and a specificity of 47.92%. ConclusionThe serum levels of CDK1 and AURKA increase with the progression of hepatitis B-associated chronic liver disease, and significant increases in serum CDK1 and AURKA have a certain value in the diagnosis of HBV-HCC.